AURA - Aura Bio P/S Multiple

Brandmark of Aura Biosciences Inc (AURA)

The normalized P/S of Aura Biosciences, Inc. (AURA) reflects market value dynamics relative to revenue, while records a new level. Aura Biosciences, Inc. (AURA) brings together elite ophthalmic oncologists, creating the conditions necessary to save patient vision. Testing stability ensures strict control over raw material supplies, and precise biopharmaceutical logistics minimize disruption risks, supporting high profitability across all medical projects.

AURA: Aura Biosciences, Inc. P/S Multiple 07/04/2022 - 11/18/2026

Analytical breakdowns for Aura Biosciences, Inc. (AURA)

- stock value and consensus price forecast:
General company analysis:AURA, Aura Biosciences Inc
Finished products of Aura Corp

The specifics of the biopharmaceutical sector, characterized by the uncertainty of Aura Biosciences, Inc. (AURA) clinical trials, make revenue a rare but critical indicator of business viability. This metric compares market capitalization with actual sales volumes, allowing for an assessment of overvaluation relative to current earnings via the price-to-sales ratio.

Competitors of Aura Biosciences, Inc.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|Candel Therapeutics - Market Cap to Revenue|Accuray Inc. (ARAY) - Price to Sales|SELLAS Life Sciences Group, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd